Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROCARDIA vs AFEDITAB CR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
Chronic stable angina,Vasospastic angina (Prinzmetal's angina),Hypertension
Hypertension,Chronic stable angina,Vasospastic angina (Prinzmetal's angina)
Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.
30-60 mg orally once daily, extended-release; maximum 90 mg/day.
2-5 hours in healthy adults; up to 6-10 hours in cirrhotic patients or elderly; clinical context: requires extended-release formulations for once-daily dosing.
Terminal elimination half-life is 6-11 hours; prolonged in hepatic impairment and elderly due to reduced clearance
Primarily metabolized by cytochrome P450 3A4 (CYP3A4) to inactive metabolites.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via bile); 0% unchanged in urine.
Renal (80% as inactive metabolites), fecal (15% as metabolites), unchanged drug (<1%)
92-98% bound to serum albumin.
92-98% bound to plasma proteins (primarily albumin)
1.0-1.5 L/kg; large distribution suggests extensive tissue penetration.
0.5-0.9 L/kg; high distribution indicates extensive tissue binding
Immediate-release: 40-60% (extensive first-pass metabolism); sustained-release: 80-90% relative to immediate-release formulation.
Oral extended-release: approximately 50-60% due to first-pass metabolism; absolute bioavailability is 45-60%
No specific dose adjustment required; use caution in severe renal impairment (GFR <30 m L/min).
No adjustment required for any degree of renal impairment, but use with caution in patients with severe renal failure due to risk of hypotension.
Child-Pugh Class A: reduce dose by 50%; Class B or C: contraindicated or use with extreme caution, reduce dose by 60-75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Not FDA-approved for pediatric use; off-label: 0.25-0.5 mg/kg/dose orally every 6-8 hours, maximum 3 mg/kg/day.
Not recommended for use in pediatric patients; safety and efficacy not established.
Initiate at lower doses (e.g., 10 mg immediate-release 3 times daily or 30 mg XL once daily); titrate slowly; monitor for hypotension and edema.
Initiate at lower end of dosing range (30 mg once daily) due to increased sensitivity to hypotensive effects and potential for reduced hepatic clearance.
No FDA-issued black box warning.
No FDA black box warning.
May cause severe hypotension especially with concomitant beta-blockers,Peripheral edema,Gingival hyperplasia,Hepatic impairment may require dose adjustment,Avoid abrupt discontinuation (may worsen angina),Increased risk of myocardial infarction in patients with coronary artery disease
Hypotension, especially with immediate-release formulations,Peripheral edema,Hepatic impairment,Increased angina/acute MI upon withdrawal or dose escalation,Beta-blocker withdrawal,Congestive heart failure
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Acute myocardial infarction (within first 4 weeks),Concomitant use with strong CYP3A4 inducers or inhibitors
Hypersensitivity to nifedipine or any component,Cardiogenic shock,Concomitant use with strong CYP3A4 inducers (e.g., rifampin),Kock pouch (ileostomy)
Grapefruit juice and grapefruit increase the AUC and Cmax of nifedipine by approximately 2-fold due to CYP3A4 inhibition; avoid concurrent consumption. Alcohol may exacerbate hypotension and vasodilatory effects. High-fat meals can delay absorption of extended-release tablets but do not significantly alter overall bioavailability.
Grapefruit juice increases nifedipine levels via CYP3A4 inhibition; avoid consumption. High-fat meals may delay absorption but do not alter overall exposure. Avoid alcohol as it can exacerbate vasodilation and hypotension.
First trimester: No increased risk of major malformations in human studies; however, in animal studies, nifedipine caused embryotoxicity and teratogenicity at high doses. Second and third trimesters: Associated with reduced uteroplacental blood flow, fetal hypoxia, and low birth weight. Tocolysis use may cause maternal hypotension and fetal distress. Overall, FDA Category C.
Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine growth restriction (IUGR), and oligohydramnios; may cause neonatal hypotension, bradycardia, and hypoglycemia if used near term. Contraindicated in pregnancy for hypertension; use only if benefit outweighs risk (e.g., tocolysis).
Nifedipine is excreted into breast milk; milk-to-plasma ratio approximately 1.0. Low relative infant dose (2-5% of maternal weight-adjusted dose). No reported adverse effects in breastfed infants. However, caution is advised, especially in preterm or low-birth-weight infants. Monitor infant for hypotension or adverse effects.
Nifedipine excreted into breast milk; M/P ratio approximately 0.42-0.77; limited human data; no adverse effects reported in infants; use with caution during breastfeeding.
No standard dose adjustment required. However, increased clearance and volume of distribution in pregnancy may require dose titration to achieve clinical effect. Start with lowest effective dose.
Plasma clearance may increase due to higher volume of distribution and metabolism; no specific dose adjustment recommended; titrate based on maternal blood pressure and response; avoid around labor due to tocolytic effect.
Nifedipine (Procardia) is a dihydropyridine calcium channel blocker with potent vasodilatory effects. Avoid sublingual administration of short-acting capsules due to risk of profound hypotension, myocardial ischemia, and stroke. Use only extended-release formulations for chronic hypertension or stable angina. May cause peripheral edema; differentiate from heart failure. Gingival hyperplasia can occur with chronic use. Contraindicated in patients with a history of hypersensitivity to dihydropyridines, cardiogenic shock, significant aortic stenosis, or within 4 weeks of myocardial infarction.
AFEDITAB CR is a controlled-release formulation of nifedipine, a dihydropyridine calcium channel blocker. Avoid grapefruit juice as it inhibits CYP3A4 metabolism, increasing nifedipine levels. Use cautiously in patients with aortic stenosis or left ventricular dysfunction due to risk of hypotension. Do not crush or chew tablets; intact shell may appear in stool.
Swallow extended-release tablets whole; do not crush, chew, or split.,Avoid grapefruit juice and grapefruit products as they increase nifedipine levels and risk of toxicity.,Report persistent swelling of ankles/feet, severe headaches, dizziness, or palpitations to your healthcare provider.,Rise slowly from sitting or lying positions to minimize orthostatic hypotension.,Practice good oral hygiene and regular dental check-ups to reduce risk of gum overgrowth.,Do not stop taking this medication abruptly; taper under medical supervision to avoid rebound angina.
Swallow the tablet whole; do not crush, chew, or break it.,Avoid grapefruit juice while taking this medication.,Do not discontinue abruptly; taper under medical supervision.,Report symptoms of hypotension like dizziness or fainting.,Limit alcohol intake as it may worsen side effects.,Monitor for fluid retention (ankle swelling) and notify doctor if worsening.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROCARDIA vs AFEDITAB CR, answered by our medical review team.
PROCARDIA is a Calcium Channel Blocker that works by Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. AFEDITAB CR is a Calcium Channel Blocker that works by Nifedipine is a dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROCARDIA and AFEDITAB CR depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROCARDIA is: Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.. The standard adult dose of AFEDITAB CR is: 30-60 mg orally once daily, extended-release; maximum 90 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROCARDIA and AFEDITAB CR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROCARDIA is classified as Category C. First trimester: No increased risk of major malformations in human studies; however, in animal studies, nifedipine caused embryotoxicity and teratogenicity at high doses. Second an. AFEDITAB CR is classified as Category C. Teratogenic effects not established; first trimester: no data in humans, animal studies show no teratogenicity; second and third trimesters: risk of fetal hypoxia, intrauterine gro. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.